Physician profile
Paul E Schackman
NPI 1144216342
$2,100.38
in general payments reported to CMS, 2019-2025
22 companies · $582 in 2025
The $582 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $165 · 2021: $87.45 · 2022: $27.90 · 2023: $363 · 2024: $300 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $292.78 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $245.65 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $217.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $203.64 | 2019-2025 | Farxiga |
| Abbott Laboratories | $190.79 | 2019-2025 | Mitraclip, Gallant, Aveir |
| Merck Sharp & Dohme LLC | $162.30 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.79 | 2019-2025 | Jardiance |
| Pfizer INC. | $117.16 | 2019-2025 | |
| Boston Scientific Corporation | $95.57 | 2023-2025 | Watchman Flx, General - Therapies |
| Amarin Pharma, INC. | $93.63 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $70.37 | 2025 | Camzyos |
| Bridgebio Pharma, INC. | $36.15 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $31.87 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $30.39 | 2025 | |
| Novo Nordisk INC | $30.26 | 2023 | Ozempic, Rybelsus |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $29.48 | 2019 | |
| Cleerly, INC. | $25.62 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Edwards Lifesciences Corporation | $24.92 | 2025 | Sapien 3 Ultra Resilia |
| Kowa Pharmaceuticals America, INC. | $24.48 | 2019-2020 | |
| Esperion Therapeutics, INC. | $15.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.82 | 2019 | |
| Allergan, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Schackman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.